title: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
authors.affiliation: Department of Medicine, University of Washington, Seattle 98101, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Psaty
authors.forename: N S
authors.initials: NS
authors.lastname: Weiss
authors.forename: C D
authors.initials: CD
authors.lastname: Furberg
authors.forename: T D
authors.initials: TD
authors.lastname: Koepsell
authors.forename: D S
authors.initials: DS
authors.lastname: Siscovick
authors.forename: F R
authors.initials: FR
authors.lastname: Rosendaal
authors.forename: N L
authors.initials: NL
authors.lastname: Smith
authors.forename: S R
authors.initials: SR
authors.lastname: Heckbert
authors.forename: R C
authors.initials: RC
authors.lastname: Kaplan
authors.forename: D
authors.initials: D
authors.lastname: Lin
authors.forename: T R
authors.initials: TR
authors.lastname: Fleming
authors.forename: E H
authors.initials: EH
authors.lastname: Wagner
mesh_terms: D015415:Biomarkers; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015415:Biomarkers; D002317:Cardiovascular Agents